Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated August 12, 2025, discloses insider trading activity in compliance with Article 19 of Regulation No. 596/2014 on market abuse. The company is a global healthcare leader headquartered in Denmark, employing approximately 78,400 people across 80 countries and marketing products in around 170 countries.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It is strictly a regulatory disclosure of a specific share transaction.
| Transaction Detail | Value |
|---|---|
| Executive Name | Ludovic Helfgott (Executive Vice President) |
| Transaction Type | Sale of Shares |
| Volume | 12,000 shares |
| Price per Share | DKK 326.00 |
| Total Value | DKK 3,912,000.00 |
| Date of Transaction | August 8, 2025 |
| Exchange | Nasdaq Copenhagen |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. The only reported change is the reduction in shareholding by the named executive.
Guidance, Outlook, and Risks
The document contains no forward-looking guidance, management commentary on future performance, or discussion of specific risks and contingencies. It serves solely as a notification of a completed transaction by a person discharging managerial responsibilities.
Key Facts for Investor Verification
- Verify the identity of the selling executive: Ludovic Helfgott, Executive Vice President.
- Confirm the transaction date (August 8, 2025) and the execution price (DKK 326.00) against market data for Nasdaq Copenhagen.
- Note that this filing does not impact the company's financial statements or operational outlook.
- Check for any subsequent filings regarding the same executive to track cumulative insider trading activity.